BioMarin to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast on Monday, March 3 at 8:00 a.m.

BioMarin to Host Fourth Quarter and Full Year 2013 Financial Results
Conference Call and Webcast on Monday, March 3 at 8:00 a.m. ET

SAN RAFAEL, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive
Officer of BioMarin, will host a conference call and webcast on Monday, March
3, at 8:00 a.m. ET to discuss fourth quarter and full year 2013 financial
results.

U.S. / Canada Dial-in Number: 877.303.6313
International Dial-in Number: 631.813.4734
Conference ID: 59525165

Replay Dial-in Number: 855.859.2056
Replay International Dial-in Number: 404.537.3406
Conference ID: 59525165

Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com. A replay of the
call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for MPS VI, a
product wholly developed and commercialized by BioMarin; Aldurazyme®
(laronidase) for MPS I, a product which BioMarin developed through a 50/50
joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride)
Tablets, for phenylketonuria (PKU), developed in partnership with Merck
Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse®
(amifampridine), which has been approved by the European Commission for the
treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates
include VIMIZIM™ (N-acetylgalactosamine 6-sulfatase), formally referred to as
GALNS, which successfully completed Phase 3 clinical development for the
treatment of MPS IVA, PEG PAL (PEGylated recombinant phenylalanine ammonia
lyase), which is currently in Phase 3 clinical development for the treatment
of PKU, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is
currently in Phase 3 clinical development for the treatment of germline BRCA
breast cancer, BMN 111, a modified C-natriuretic peptide, which is currently
in Phase 2 clinical development for the treatment of achondroplasia, BMN 701,
a novel fusion of acid alpha glucosidase (GAA) with a peptide derived from
insulin like growth factor 2, which is currently in Phase 1/2 clinical
development for the treatment of Pompe disease, BMN 190, a recombinant human
tripeptidyl peptidase-1 (rhTPP1) for the treatment of late-infantile neuronal
ceroid lipofuscinosis (CLN2), a form of Batten Disease, which is currently in
Phase 1 and BMN 270, an AAV-factor VIII vector, for the treatment of
hemophilia A.

For additional information, please visit www.BMRN.com. Information on
BioMarin's website is not incorporated by reference into this press release.

CONTACT: Investors
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558
        
         Media
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.